Key finding — Both microdose and placebo groups reported improved wellbeing, but the difference between them was negligible — indicating that much of the perceived benefit of microdosing is driven by expectation rather than pharmacology.
Study at a glance
| Field | Detail |
|---|---|
| Institution | Imperial College London |
| Design | Self-blinding, placebo-controlled citizen-science study |
| Sample size | 191 participants |
| Intervention | Self-administered microdoses vs. placebo, self-blinding protocol |
| Year | 2021 |
| Condition | Microdosing (wellbeing and cognition) |
| Journal | eLife |
| Evidence | emerging |
Limitations
Participants sourced and dosed their own substances; reliance on self-report and an unusual self-blinding design limits precision, though the placebo control is a major strength.
Editorial note
An ingenious low-cost design that brought a placebo control to microdosing for the first time at scale. Its humbling result — most benefit attributable to expectancy — reshaped how the field discusses microdosing claims.
Summary written by MMI Editorial for clarity. Always consult the primary source for full methodology and results. The confidence rating reflects our assessment of evidence strength.